xRead - September 2022

Wise et al.

Page 397

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion

Combination therapy was more effective than either drug alone in reducing TSS and nasal congestion.

Oral cetirizine + pseudoephedrine was superior to budesonide in reducing nasal congestion when exposed to HDM.

montelukast were equally effective in improving RQLQ, total symptoms, and nPIF, except for the sleep domain (loratadine-montelukast better).

Fexofenadine-pseudoephedrine was more effective in reducing all symptoms following a single exposure to allergen; onset of action: 45 minutes.

Nasal congestion by photographs was similar between groups. Cetirizine-pseudoephedrine was significantly better in improving all subjective symptoms.

Significant improvement in nasal edema and secretions and nasal/ocular symptoms of rhinoconjunctivitis in the treatment group compared to placebo.

Combination therapy significantly more effective in improving total symptom score and nasal congestion, produced greater improvement in daily activities and work productivity.

TSS, morning instantaneous TSS, nasal congestion score

Rhinomanometry, nasal cavity images, nasal congestion

RQLQ, nasal symptoms, nPIF Fexofenadine-pseudoephedrine and loratadine Single exposure major symptom complex, total symptom complex, individual symptoms Nasal congestion by photographs and digital airflow, nasal secretions, nasal and ocular symptoms Acoustic rhinometry, endoscopic inferior turbinate photography, QOL Total symptoms, nasal congestion

1 Desloratadine-pseudoephedrine; 2 Desloratadine; 3 Pseudoephedrine

1 Cetirizine + prolonged release pseudoephedrine; 2 Budesonide nasal spray

1 Fexofenadine-pseudoephedrine; 2 Loratadine + montelukast

1 Fexofenadine-pseudoephedrine; 2 Placebo

1 Cetirizine-pseudoephedrine;

2 Xylometazoline nasal spray

1 Loratadine-pseudoephedrine; 2 Placebo

1 Fexofenadine-pseudoephedrine; 2 Fexofenadine; 3 Pseudoephedrine

Study Year LOE

Pleskow et al. 1460 2005 1b RCT (n = 1047): Zieglmayer et al. 1449

2005 1b RCT (n = 36):

Moinuddin et al. 1467 2004 1b RCT (n = 72):

Berkowitz et al. 1044 2002 1b RCT (n = 298):

Stubner et al. 1468 2001 1b RCT (n = 36):

McFadden et al. 1452 2000 1b RCT (n = 20):

Sussman et al. 1457 1999 1b RCT (n = 651):

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.